Sarepta Therapeutics Inc (NASDAQ:SRPT) shot up 6.4% during mid-day trading on Monday after Credit Suisse Group raised their price target on the stock from $81.00 to $100.00. Credit Suisse Group currently has an outperform rating on the stock. Sarepta Therapeutics traded as high as $80.23 and last traded at $79.10. 2,785,699 shares traded hands during trading, an increase of 63% from the average session volume of 1,704,225 shares. The stock had previously closed at $74.36.
Several other brokerages have also recently commented on SRPT. Leerink Swann reaffirmed a “positive” rating and set a $92.00 target price (up from $79.00) on shares of Sarepta Therapeutics in a report on Tuesday. HC Wainwright raised their target price on shares of Sarepta Therapeutics from $75.00 to $92.00 and gave the stock a “buy” rating in a report on Monday. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $76.12 target price (down from $83.00) on shares of Sarepta Therapeutics in a report on Monday. SunTrust Banks raised their target price on shares of Sarepta Therapeutics to $76.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. Finally, Morgan Stanley raised their target price on shares of Sarepta Therapeutics from $63.00 to $64.00 and gave the stock an “overweight” rating in a report on Tuesday, March 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $72.17.
A number of large investors have recently made changes to their positions in the stock. Xact Kapitalforvaltning AB bought a new position in Sarepta Therapeutics in the fourth quarter valued at approximately $345,000. Handelsbanken Fonder AB bought a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $1,196,000. Delek Group Ltd. bought a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $2,056,000. Vanguard Capital Wealth Advisors bought a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $295,000. Finally, MetLife Investment Advisors LLC bought a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $1,538,000. 85.14% of the stock is currently owned by institutional investors and hedge funds.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). The company had revenue of $57.30 million for the quarter, compared to the consensus estimate of $57.33 million. Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. The business’s quarterly revenue was up 961.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.71) EPS. analysts expect that Sarepta Therapeutics Inc will post -1.18 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Sarepta Therapeutics (SRPT) Shares Up 6.4% After Analyst Upgrade” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3260442/sarepta-therapeutics-srpt-shares-up-6-4-after-analyst-upgrade.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.